The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease

Author(s): Struve, F. A., Patrick, G., Booker, J. G., Nave, D. W.

Journal/Book: Amer J Geriatr Psychiatr. 1999; 7: 1400 K St N W, Ste 1101, Washington, DC 20005, USA. Amer Psychiatric Press, Inc. 349-352.

Abstract: Donepezil is a cholinesterase inhibitor used for the treatment of patients with mild to moderately severe Alzheimer's disease (AD). The purpose of this study was to determine the effect of treatment with donepezil 5 mg qd on cognitive evoked potentials (EPs) of patients with AD. Although treatment with donepezil did not normalize EP latencies, treatment was associated with a significant decrease in the auditory P300 latency (mean latency pretreatment = 401.5 msec; posttreatment = 392.7 msec.; P = 0.04), and the visual P300 latency (mean latency pretreatment = 605.7 msec; posttreatment = 580.3 msec; P = 0.04). Treatment with donepezil had no discernible effect on auditory or visual P300 EP amplitudes.

Note: Article Reeves RR, VA Med Ctr 116A, Dept Psychiat, 1500 E Woodrow Wilson, Jackson,MS 39216 USA

Keyword(s): INDANONE BENZYLPIPERIDINE INHIBITORS; ACETYLCHOLINESTERASE; SERIES

Zurück | Weiter